Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Progressive Muscular Atrophy: early-phase trial registry

2 of 5 indexed Progressive Muscular Atrophy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Progressive Muscular Atrophy: 5 US clinical trials tracked, 2 recruiting.

Progressive Muscular Atrophy is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of Miami, running 3 of these trials.

Enrollment posture brief

Registry condition progressive-muscular-atrophy

OPEN 2 | RECR 40% | LATE 0 | EARLY 1 | RANK #3391 | SPON 3

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Progressive Muscular Atr (th…40%
Open-enrollment share among volume-matched conditions near Progressive Muscular Atrophy

Progressive Muscular Atrophy lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Progressive Muscular Atrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Progressive Muscular Atrophy is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Progressive Muscular Atrophy research.

    University of Miami accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.

  3. Typical Progressive Muscular Atrophy enrolment sits around 217 participants.

    Median target enrolment is 217 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.

  4. Progressive Muscular Atrophy research leans observational.

    1 interventional and 4 observational studies make up this index (20% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Progressive Muscular Atrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Levetiracetam Biological
1 trials
Digital Speech and Handwriting Assessment Behavioral
1 trials

US sites by state

Facility locations filed on Progressive Muscular Atrophy trials. A trial with sites in several states counts in each.

Pennsylvania 3 trials
Kansas 3 trials
Florida 3 trials
North Carolina 2 trials
Texas 1 trials
Oregon 1 trials
New York 1 trials
Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Progressive Muscular Atrophy page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Progressive Muscular Atrophy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • University of Miami sponsors the most Progressive Muscular Atrophy trials on record, review their full trial history before evaluating a specific study. See University of Miami's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Progressive Muscular Atrophy condition card totals 5 registered trials; most-linked intervention Levetiracetam; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.